Trial intelligence / Profile preview

Stellisept mucosa vs Octenisept for oral antisepsis in healthy volunteers

2006-000062-37Phase 3Completed

Sponsor
BODE Chemie
Start
Mar 2006
Modality
Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of octenidine in Oral infections and Oral mucosal colonization (2 arms), sponsored by BODE Chemie. Primary endpoints: antiseptic efficacy and local tolerability. Started Mar 2006; status: completed.

02

Drugs

octenidine
03

Conditions

Oral infectionsOral mucosal colonization

Beyond the preview

Go deeper on 2006-000062-37.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-000062-37.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call